Officer Marshall Fordyce Files Intent to Sell $2.8M in Stock
VERA has more than doubled off its 52-week low of $19.066.
Summary
An officer and director of Vera Therapeutics has filed an intent to sell $2.84 million worth of stock, continuing a pattern of executive share dispositions.
Key Events · Ownership and Investor Activity · VERA
-
Continuation of Prior Sales
This proposed sale follows previous dispositions by Fordyce totaling 41,451 shares for $1.69 million over the last three months, which were executed under a 10b5-1 plan.
-
Shares from Option Exercise
The shares to be sold were acquired through the exercise of stock options, indicating a monetization of compensation rather than a direct market sale of existing holdings.
-
Ongoing Executive Distribution
This filing contributes to a pattern of executive share distribution, with net insider selling of $1.69 million in open-market transactions over the past 90 days.
Analysis · VERA · Life Sciences
Marshall Fordyce, an officer and director, has filed a Form 144 indicating an intent to sell 74,000 shares of common stock, valued at approximately $2.84 million. This follows previous sales by Fordyce totaling $1.69 million over the past three months, which were part of a 10b5-1 plan. While these sales are likely pre-planned and related to option exercises for liquidity, the cumulative distribution by a key executive adds to selling pressure, especially given the company's recent cash burn reported in Q1 2026.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.1% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VERA was trading at $38.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $19.07 to $56.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.